News

Ideal agent for insomnia not always clear cut

Publish date: March 10, 2014

 

EXPERT ANALYSIS AT THE NPA PSYCHOPHARMACOLOGY UPDATE

Dr. Doghramji disclosed that he is a consultant for UCB, Teva Pharmaceuticals, Vanda Pharmaceuticals, and Jazz Pharmaceuticals, and that he holds stock in Merck.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Antipsychotics linked to sudden cardiac death risk
MDedge Psychiatry
Lithium-induced diabetes insipidus: Prevention and management
MDedge Psychiatry
HIV: How to provide compassionate care
MDedge Psychiatry
A teen who is wasting away
MDedge Psychiatry
Novel intervention improves outcomes in homeless schizophrenia patients
MDedge Psychiatry
Family narratives and the intergenerational transmission of resilience
MDedge Psychiatry
Depression, anxiety common in SLE patients
MDedge Psychiatry
Depression accounts for psoriatics’ increased MI risk
MDedge Psychiatry
Who are the mentally ill? Take a survey
MDedge Psychiatry
A different take on sensory deprivation
MDedge Psychiatry